

CANCER RESEARCH & ONCOLOGY

OCTOBER 9th ~ 10th 2019

Date	Time	Track	Presentation Title	Speaker
9-Oct	06:00 - 07:00 AM	Novel Cancer Therapeutics and Cancer Prevention	Multilevel Interventions in Cancer Prevention and Control: A Community-Based Translational Research Framework to Address Prostate Cancer Disparities	Brian Rivers, PhD, MPH Director of the Cancer Health Equity Institute Morehouse School of Medicine (MSM)
9-Oct	07:30 - 08:30 AM	Tumor Drug Resistance and Tumor Evolution	Keynote Presentation: Pairing protein profiling with drug screens uncovers an effective therapy against high risk leukemia	Ernesto Diaz-Flores, PhD Assistant Adjunct Professor in the Department of Pediatrics/Hematology at UCSF
9-Oct	09:00 - 10:00 AM	Novel Cancer Therapeutics and Cancer Prevention	Start at the End: A Strategy for Developing and Delivering Advanced Diagnostic Tests to improve Prostate Cancer Patient Outcomes	Stephen Pennington Professor of Proteomics, Founder, CEO and CSO Atturos Ltd. C/O UCD Conway Institute University College Dublin
9-Oct	10:30 - 11:30 AM	Tumor Drug Resistance and Tumor Evolution	A practical guide for multiplexed ion beam imaging to reveal tumor immunobiology	Selena Ferrian Sr.Staff Scientist/LSRP3, Stanford University
9-Oct	10:30 - 11:30 AM	Novel Cancer Therapeutics and Cancer Prevention	Newly Diagnosed Ovarian Cancer: Surgical Options	Mitchel S. Hoffman, MD Full-time faculty member, Department of Gynecologic Oncology, Moffitt Cancer Center, and Professor, USF Morsani College of Medicine
9-Oct	12:00 - 01:00 PM	Molecular Guidance Versus Standard of Care	Next Steps in Personalized Medicine- Using Genomics and Imaging For Treatment Selection in Early Stage Prostate Cancer	Anson Tharayanil Medical Science Liaison (Urology), Genomic Health, Inc.
9-Oct	12:00 - 01:00 PM	Novel Cancer Therapeutics and Cancer Prevention	What is New in Surgical Management of Invasive Bladder Cancer in 2020	Khurshid Guru, MD Surgeon, Dept of Urology, Chair, Dept of Urology, Director, Applied Technology Laboratory for Advanced Surgery, Robert P. Huben Endowed Professor of Oncology, Roswell Park Cancer Institute

9-Oct	01:30 - 02:30 PM	Tumor Drug Resistance and Tumor Evolution	Tumor processing for the isolation and visualization of Tumor Infiltrating Leukocytes	Josh Mahlios, PhD Senior Marketing Product Manager, Miltenyi Biotec
10-Oct	06:00 - 07:00 AM	Novel Cancer Therapeutics and Cancer Prevention	Highly-efficient and -specific genome editing with Cas9 nickase ribonucleoproteins in Primary T-cells	Jacob Lamberth R&D Scientist, Genome and Epigenome Editing: MilliporeSigma
10-Oct	07:30 - 08:30 AM	Novel Cancer Therapeutics and Cancer Prevention	Keynote Presentation: Cancer Prevention for the Practicing Oncologist - Recommendations for Cancer Patients and Their Families	Ernest Hawk, MD, MPH Vice President & Division Head for Cancer Prevention & Population Sciences, University of Texas MD Anderson Cancer Center
10-Oct	07:30 - 08:30 AM	Novel Cancer Therapeutics and Cancer Prevention	Keynote Presentation: Cancer Prevention for the Practicing Oncologist - Recommendations for Cancer Patients and Their Families	
10-Oct	07:30 - 08:30 AM	Novel Cancer Therapeutics and Cancer Prevention	Keynote Presentation: Cancer Prevention for the Practicing Oncologist - Recommendations for Cancer Patients and Their Families	
10-Oct	07:30 - 08:30 AM	Novel Cancer Therapeutics and Cancer Prevention	Keynote Presentation: Cancer Prevention for the Practicing Oncologist - Recommendations for Cancer Patients and Their Families	
10-Oct	07:30 - 08:30 AM	Novel Cancer Therapeutics and Cancer Prevention	Keynote Presentation: Cancer Prevention for the Practicing Oncologist - Recommendations for Cancer Patients and Their Families	
10-Oct	07:30 - 08:30 AM	Novel Cancer Therapeutics and Cancer Prevention	Keynote Presentation: Cancer Prevention for the Practicing Oncologist - Recommendations for Cancer Patients and Their Families	Jeffrey N Weitzel, MD Director, Clinical Cancer Genetics, Professor, Director, Cancer Screening; Prevention City of Hope
10-Oct	09:00 - 10:00 AM	Tumor Drug Resistance and Tumor Evolution	Dynamic evolution of unstable genomes: insights from in vitro experiments and cancer genome analysis	Cheng-Zhong Zhang, PhD Assistant Professor, Biomedical Informatics, Harvard Medical School , and Assistant Professor, Biostatistics & Computational Biology, Dana-Farber Cancer Institute
10-Oct	09:00 - 10:00 AM	Novel Cancer Therapeutics and Cancer Prevention	Next Generation Targets for Immuno-Oncology	Anthony Persen, PhD Sr. Director, Protein Business Unit, R&D Systems

10-Oct	10:30 - 11:30 AM	Molecular Guidance Versus Standard of Care	Transcriptional Profiling of the Pediatric Tumor Microenvironment	Troy McEachron, PhD Assistant Professor of Research, Translational Genomics, University of Southern California, Keck School of Medicine
10-Oct	10:30 - 11:30 AM	Tumor Drug Resistance and Tumor Evolution	Whole genome imaging for sensitive and accurate analysis of structural variations in cancer	Sven Bocklandt, PhD Sr. Director of Scientific Affairs & Marketing, Bionano Genomics
10-Oct	12:00 - 01:00 PM	Tumor Drug Resistance and Tumor Evolution	Tumor Mutation Burden: Challenges and opportunities of measuring and interpreting tumor mutational burden for patient care	Ravindra Kolhe, MD, PhD Associate Professor, Pathology; Associate Director, Residency Program; Medical Director, Cytogenetics Laboratory AUMC.
10-Oct	01:30 - 02:30 PM	Molecular Guidance versus Standard of Care	Precision oncology: Biomarkers for treatment selection in metastatic castration resistant prostate cancer	Tian Zhang, MD, MHS Assistant Professor of Medicine, Division of Medical Oncology, Department of Medicine, Duke Cancer Institute